Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer

Kenneth M. Wong, Theodore Scott Nowicki, Carmelo Puccio, Tauseef Ahmed, Raj Tiwari, Jan Geliebter, Augustine Moscatello

Department of Medical Oncology, Westchester Medical Center, Valhalla, USA.
Department of Microbiology and Immunology, New York Medical College, Valhalla, USA.
Department of Otolaryngology—Head and Neck Surgery, New York Eye and Ear Infirmary, New York, USA.
Department of Otolaryngology—Head and Neck Surgery, Westchester Medical Center, Valhalla, USA.

DOI: 10.4236/jct.2012.32018                

Abstract

Background: Anaplastic thyroid cancer (ATC), while rare, carries a uniformly poor prognosis. Current treatment includes surgery when possible, radiotherapy, and chemotherapy. Multiple chemotherapeutic agents are in the process of clinical testing, and promising agents include those in the tyrosine kinase inhibitor family. Our patient represents a novel case of ATC treated with sunitinib, one such tyrosine kinase inhibitor. Methods/Results: We utilized the experimental sunitinib in conjunction with radiation therapy to treat a patient with aggressive ATC in whom curative resection was unable to be achieved due to carotid sheath and tracheal involvement. The patient had marked clinical response and sustained stable disease for 8 months, which coincides with reported data regarding sunitinib to treat other thyroid malignancies. Conclusion: Our case illustrates the efficacy of sunitinib therapy as a possible adjunct in the treatment of ATC.

Keywords

Sunitinib; Anaplastic Thyroid Cancer; Tyrosine Kinase Inhibitor; Chemotherapy; ATC

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. R. Shaha, “Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer,” Laryngoscope, Vol. 114, No. 3, 2004, pp. 393-402. doi:10.1097/00005537-200403000-00001
[2]	J. Rosai, M. L. Cargangiu and R. Delellis, “Tumours of the Thyroid Gland,” In: A. P. Stout, Ed., Atlas of Tumour Pathology, 3rd Series, Fascicle 5, Armed Forces Institute of Pathology, Washington DC, 1992.
[3]	J. P. Pierie, A. Muzikansky, R. D. Gaz, W. C. Faquin and M. J. Ott, “The effect of Surgery and Radiotherapy on Outcome of Anaplastic Thyroid Carcinoma,” Annals of Surgical Oncology, Vol. 9, No. 1, 2002, pp. 57-64. doi:10.1245/aso.2002.9.1.57
[4]	B. Busnardo, O. Daniele, M. R. Pelizzo, et al., “A Multimodality Therapeutic Approach in Anaplastic Thyroid Carcinoma: Study on 39 Patients,” Journal of Endocrinological Investigation, Vol. 23, No. 11, 2000, pp. 755-761.
[5]	P. I. Haigh, P. H. Ituarte, H. S. Wu, et al., “Completely Resected Anaplastic Thyroid Carcinoma Combined with Adjuvant Chemotherapy and Irradiation Is Associated with Prolonged Survival,” Cancer, Vol. 91, No. 12, 2001, pp. 2335-2342. doi:10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1
[6]	L. Q. Chow and S. G. Eckhardt, “Sunitinib: From Rational Design to Clinical Efficacy,” Journal of Clinical Oncology, Vol. 25, No. 7, 2007, pp. 884-896. doi:10.1200/JCO.2006.06.3602
[7]	A. Ravaud, C. de la Fouchardière, J. Asselineau, et al., “Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU,” Oncologist, Vol. 15, No. 2, 2010, pp. 212-213. doi:10.1634/theoncologist.2009-0303
[8]	L. L. Carr, D. A. Mankoff, B. H. Goulart, et al., “Phase II Study of Daily Sunitinib in FDG-PET-Positive, IodineRefractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation,” Clinical Cancer Research, Vol. 16, No. 21, 2010, pp. 5260-5268. doi:10.1158/1078-0432.CCR-10-0994
[9]	E. W. Cohen, B. M. Needles, K. J. Cullen, et al., “Phase 2 Study of Sunitinib in Refractory Thyroid Cancer,” Journal of Clinical Oncology, Vol. 26, 2008, p. 6025.
[10]	S. J. Dawson, N. M. Conus, G. C. Toner, et al., “Sustained Clinical Responses to Tyrosine Kinase Inhibitor Sunitinib in Thyroid Carcinoma,” Anticancer Drugs, Vol. 19, No. 5, 2008, pp. 547-552. doi:10.1097/CAD.0b013e3282fc6cf7
[11]	J. M. Cleary, P. M. Sadow, G. W. Randolph, et al., “Neoadjuvant Treatment of Unresectable Medullary Thyroid Cancer with Sunitinib,” Journal of Clinical Oncology, Vol. 28, No. 23, 2010, pp. e390-e392. doi:10.1200/JCO.2009.27.4225
[12]	P. Kaldrymides, I. Kostoglou-Athanassiou, A. Gkountouvas, E. Veniou and N. Ziras, “Partial Remission of Metastatic Papillary Thyroid Carcinoma with Sunitinib. Report of a Case and Review of the Literature,” Endocrine, Vol. 37, No. 1, 2010, pp. 6-10. doi:10.1007/s12020-009-9290-z
[13]	S. M. Wiseman, H. Masoudi, P. Niblock, et al., “Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment,” Annals of Surgical Oncology, Vol. 14, No. 2, 2007, pp. 719-729. doi:10.1245/s10434-006-9178-6
[14]	Y. E. Nikiforov, “Genetic Alterations Involved in the Transition from Well-Differentiated to Poorly Differentiated and Anaplastic Thyroid Carcinomas,” Endocrine Pathology, Vol. 15, No. 4, 2004, pp. 319-327. doi:10.1385/EP:15:4:319
[15]	R. A. DeLellis, “Pathology and Genetics of Thyroid Carcinoma,” Journal of Surgical Oncology, Vol. 94, No. 8, 2006, pp. 662-669. doi:10.1002/jso.20700
[16]	R. M. Quiros, H. G. Ding, P. Gattuso, R. A. Prinz and X. Xu, “Evidence That One Subset of Anaplastic Thyroid Carcinomas Are Derived from Papillary Carcinomas Due to BRAF and p53 Mutations,” Cancer, Vol. 103, No. 11, 2005, pp. 2261-2268. doi:10.1002/cncr.21073
[17]	R. C. Smallridge, L. A. Marlow and J. A. Copland, “Anaplastic Thyroid Cancer: Molecular Pathogenesis and Emerging Therapies,” Endocrine-Related Cancer, Vol. 16, No. 1, 2009, pp. 17-44. doi:10.1677/ERC-08-0154
[18]	L. Santarpia, A. K. El-Naggar, G. J. Cote, J. N. Myers and S. I. Sherman, “Phosphatidylinositol 3-kinase/akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer,” Journal of Clinical Endocrinology & Metabolism, Vol. 93, No. 1, 2008, pp. 278-284. doi:10.1210/jc.2007-1076
[19]	G. García-Rostán, A. M. Costa, I. Pereira-Castro, et al., “Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer,” Cancer Research, Vol. 65, No. 22, 2005, pp. 10199-10207. doi:10.1158/0008-5472.CAN-04-4259
[20]	A. Yeramian, A. Sorolla, A. Velasco, et al., “Inhibition of Activated Receptor Tyrosine Kinases by Sunitinib Induces Growth Arrest and Sensitizes Melanoma Cells to Bortezomib by Blocking Akt Pathway,” International Journal of Cancer, Vol. 130, No. 4, 2012, pp. 967-978. doi:10.1002/ijc.26096
[21]	F. Yang, V. Jove, H. Xin, M. Hedvat, T. E. Van Meter and H. Yu, “Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways,” Molecular Cancer Research, Vol. 8, No. 1, 2010, pp. 35-45. doi:10.1158/1541-7786.MCR-09-0220
[22]	M. D’Agostino, P. Voce, M. Celano, et al., “Sunitinib Exerts Only Limited Effects on the Proliferation and Differentiation of Anaplastic Thyroid Cancer Cells,” Thyroid, Vol. 22, No. 2, 2012, pp. 138-144.
[23]	M. K. Gule, Y. Chen, D. Sano, et al., “Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model,” Clinical Cancer Research, Vol. 17, No. 8, 2011, pp. 2281-2291. doi:10.1158/1078-0432.CCR-10-2762